Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DARUNAVIR

All products: not a benefit

Other products in the same Health Canada class (J05A, J05AE) — coverage varies; not interchangeable

  • Atazanavir (Reyataz): general benefit, Not a benefit
  • Fosamprenavir (Telzir): general benefit
  • Nelfinavir (Viracept): general benefit
  • Ritonavir (Norvir): general benefit
  • Nirmatrelvir + ritonavir (Paxlovid): limited Use 673, 674, 675
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

48 more in the class list below

Prezista · DIN 02324024 · 600mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-03-01 — choose a marketed DIN from the same-category list.Discontinued 2024-03-01 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-03-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-03-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Prezista · DIN 02324024 Manufacturer: Janssen Inc.; listing date 2010-03-02 Health Canada: Cancelled post market since 2024-03-01 · brand PREZISTA · ATC J05AE10 DARUNAVIR · form Tablet · route Oral · ingredients DARUNAVIR (DARUNAVIR ETHANOLATE) 600 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Prezista: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80950 · Verify on the e-Formulary ↗ (DIN 02324024)

Source record
DIN 02324024: Prezista Raw flags: notABenefit=Y, sec3=Y Item: 081800337; group id 69; item number 0136; lccId None; manufacturer id JAN Source form: Tab; strength: 600mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02324024 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80950
Interchangeable products
Apo-Darunavir · DIN 02487241 · $4.2970 Auro-Darunavir · DIN 02486121 · $4.2970 Darunavir · DIN 02521342 · $4.2970
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2024-03-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

FOSAMPRENAVIR CALCIUM

· 2 products · General benefit · strengths: 50mg/mL, 700mg · Oral Susp, Tab

NELFINAVIR MESYLATE

· 2 products · General benefit · strengths: 250mg, 625mg · Tab

RITONAVIR

· 2 products · General benefit · strengths: 100mg · Tab

NIRMATRELVIR & RITONAVIR

· 2 products · Limited Use, codes 673, 674, 675 · strengths: 150mg & 100mg · Tab-20 Pk, Tab-30 Pk

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hiv-1 infection
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, DORAVIRINE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, LOPINAVIR & RITONAVIR, RALTEGRAVIR POTASSIUM CABOTEGRAVIR · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080949.PDF; date 2025-06-30; DIN 02497204; fetched 2026-09-10 Product monograph CABOTEGRAVIR & RILPIVIRINE · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080951.PDF; date 2025-06-30; DIN 02497220; fetched 2026-09-10 Product monograph DORAVIRINE · General benefit 1 Indications PIFELTRO® (doravirine) is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older and weighing at least 35kg without past or present evidence of viral resistance to doravirine. 1.1 Pediatrics Pediatrics ( 12 to < 18 years of age): The safety and efficacy of PIFELTRO® in pediatric patients  12 years of age and weighing at least 35 kg receiving doravirine 100 mg once daily has been established (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical Trials). PM: https://pdf.hres.ca/dpd_pm/00081853.PDF; date not captured; DIN 02481545; fetched 2026-09-10 Product monograph EFAVIRENZ · Listed, not a benefit (1), General benefit (4) INDICATIONS AND CLINICAL USE Mylan-Efavirenz (efavirenz) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00076879.PDF; date AUG 29, 2024; DIN 02381524; fetched 2026-09-10 Product monograph EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE · General benefit INDICATIONS AND CLINICAL USE TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR (efavirenz [EFV]/emtricitabine [FTC]/tenofovir disoproxil fumarate [TDF]) is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. PM: https://pdf.hres.ca/dpd_pm/00056758.PDF; date June 1, 2020; DIN 02393549; fetched 2026-09-10 Product monograph EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE · General benefit INDICATIONS AND CLINICAL USE Treatment of HIV-1 Infection TRUVADA is indicated in combination with other antiretroviral agents (such as non- nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. PM: https://pdf.hres.ca/dpd_pm/00046237.PDF; date July 5, 2018; DIN 02274906; fetched 2026-09-10 Product monograph LOPINAVIR & RITONAVIR · General benefit Indications KALETRA (lopinavir/ritonavir) is indicated in combination with other antiretroviral agents when therapy is warranted for the treatment of HIV-1 infection. PM: https://pdf.hres.ca/dpd_pm/00085373.PDF; date 2026-07-14; DIN 02243644; fetched 2026-09-10 Product monograph NEVIRAPINE · Listed, not a benefit (2), General benefit (5) INDICATIONS AND CLINICAL USE AURO-NEVIRAPINE (nevirapine) is indicated as an alternative for:  treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00058912.PDF; date not captured; DIN 02318601; fetched 2026-09-10 Product monograph RALTEGRAVIR POTASSIUM · General benefit 1 INDICATIONS Adults ISENTRESS® and ISENTRESS HD® (raltegravir) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. 1.1 Pediatrics Pediatrics (2 - 18 years of age and weighing at least 7kg): ISENTRESS® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in children and adolescents 2 years of age and older with body weight at least 7 kg. PM: https://pdf.hres.ca/dpd_pm/00073112.PDF; date November 9, 2007; DIN 02301881; fetched 2026-09-10 Product monograph TENOFOVIR DISOPROXIL · Limited Use, codes 517, 518, 519, 520, 521, 522 INDICATIONS AND CLINICAL USE HIV-1 Infection VIREAD (tenofovir disoproxil fumarate [TDF]) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00045932.PDF; date June 13, 2018; DIN 02247128; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Auro-Darunavir (darunavir), co-administered with 100 mg ritonavir, and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in patients ≥ 40 kg. For a description of the clinical data in support of this indication, refer to 14 CLINICAL TRIALS. 1.1 Pediatrics Pediatrics (≥ 40 kg): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of darunavir in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS). Auro-Darunavir co-administered with low-dose ritonavir, and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in treatment-experienced pediatric patients ≥ 40 kg (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS). 1.2 Geriatrics Geriatrics (>65 years of age) Clinical studies of darunavir did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, caution should be exercised in the administration and monitoring of Auro-Darunavir in elderly patients, refle… https://pdf.hres.ca/dpd_pm/00073833.PDF PM date: December 7, 2023 Source product: AURO-DARUNAVIR; DIN 02486121; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Prezista: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026